Ozempic vs Wegovy: both semaglutide, but approved for different uses and doses. Labels, STEP 2 dose results, heart and kidney trials, side effects and prices checked October 6, 2026.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key takeaways
- Ozempic and Wegovy both contain semaglutide from Novo Nordisk; Ozempic is approved for type 2 diabetes and Wegovy for chronic weight management.[1]
- Ozempic's highest labeled dose is 2 mg a week; Wegovy's maintenance dose is 2.4 mg, and Wegovy HD is 7.2 mg.[2]
- In STEP 2, adults with type 2 diabetes lost an average of 9.6% on semaglutide 2.4 mg, 7.0% on 1.0 mg and 3.4% on placebo at 68 weeks.[3]
- On 2026-10-06, Novo Nordisk listed Ozempic at $1,027.51 per pen package and Wegovy at $1,349.02 per package; both list at $675 a month from January 1, 2027.[13]
- Medicare Part D covers Ozempic for diabetes; the temporary Medicare GLP-1 Bridge covers Wegovy for weight management with a $50 copay for people who meet its criteria.[15]
The short answer
Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic is FDA approved for adults with type 2 diabetes (blood sugar, plus heart and kidney protection in certain patients) at up to 2 mg a week; Wegovy is approved for chronic weight management, heart-risk reduction in adults with heart disease and overweight or obesity, and MASH, at up to 2.4 mg a week (7.2 mg with Wegovy HD). Ozempic is not approved for weight loss.
Scorecards
| Ozempic (semaglutide): approved uses and how it differs from WegovyFDA approved for another usePrescriptionInjection | Wegovy (semaglutide): uses, side effects, cost and FDA statusFDA approved for weight managementPrescriptionInjection | |
|---|---|---|
| Medical supervision | — | Required |
No overall score and no winner: what matters depends on you. Hover a value for its definition.
Facts side by side
| Ozempic (semaglutide): approved uses and how it differs from WegovyFDA approved for another usePrescriptionInjection | Wegovy (semaglutide): uses, side effects, cost and FDA statusFDA approved for weight managementPrescriptionInjection | |
|---|---|---|
| Purpose | Improve glycemic control, as an adjunct to diet and exercise; Reduce the risk of major adverse cardiovascular events; Reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death | Reduce excess body weight and maintain weight reduction long term (with reduced-calorie diet and increased physical activity); Reduce excess body weight and maintain weight reduction long term (injection); Reduce the risk of major adverse cardiovascular events (CV death, nonfatal heart attack, nonfatal stroke); Noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3), accelerated approval (injection); Weight reduction and maintenance, and cardiovascular risk reduction (Wegovy tablets) |
| Class or type | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Regulatory status | FDA approved for another usePrescriptionInjection | FDA approved for weight managementPrescriptionInjection |
| Prescription required | Yes | Yes |
| How it works | Ozempic (semaglutide) is FDA approved for type 2 diabetes, not weight management: approved uses, how it differs from Wegovy, side effects, counterfeit warnings and prices. | Wegovy (semaglutide): FDA-approved uses, who the label covers, how it is taken in general, trial results, side effects, boxed warning and dated prices. |
| How it is done or taken | Injection | Injection |
| How often | Weekly | Weekly |
| Average outcomes in studies |
|
|
| Main risks |
|
|
| Cost (dated) | from 25 USD per month with commercial coverage (max savings $100 a month; government beneficiaries excluded) (checked October 6, 2026) | from 25 USD per month with commercial coverage (max savings $100 a month; government beneficiaries excluded) (checked October 6, 2026) |
| Official resources | dailymed.nlm.nih.gov | dailymed.nlm.nih.gov |
What the trials showed
- STEP 2 (NCT03552757) 1,210 adults with type 2 diabetes and BMI 27+, 68 weeks, double blind: weight change -9.6% with semaglutide 2.4 mg (Wegovy dose) vs -7.0% with 1.0 mg (an Ozempic dose) vs -3.4% with placebo; difference between doses -2.7 points.[3]
Side effects compared
| Ozempic (semaglutide): approved uses and how it differs from WegovyFDA approved for another usePrescriptionInjection | Wegovy (semaglutide): uses, side effects, cost and FDA statusFDA approved for weight managementPrescriptionInjection | |
|---|---|---|
| From the label |
|
|
Cost and coverage
| Option | Price | Amount | Basis | Checked on |
|---|---|---|---|---|
| Ozempic (semaglutide): approved uses and how it differs from Wegovy | Self-pay / cash | 349 USD | per month, pens 0.25 mg, 0.5 mg or 1 mg, NovoCare Pharmacy | October 6, 2026 |
| Ozempic (semaglutide): approved uses and how it differs from Wegovy | Self-pay / cash | 499 USD | per month, 2 mg pen, NovoCare Pharmacy | October 6, 2026 |
| Ozempic (semaglutide): approved uses and how it differs from Wegovy | Self-pay / cash | 199 USD | per month, first 2 fills of 0.25 mg and 0.5 mg for new patients, through 2026-12-31 | October 6, 2026 |
| Ozempic (semaglutide): approved uses and how it differs from Wegovy | With savings program | 25 USD | per month with commercial coverage (max savings $100 a month; government beneficiaries excluded) | October 6, 2026 |
| Wegovy (semaglutide): uses, side effects, cost and FDA status | List price | 1,349.02 USD | per package (pen, HD pen or pill) | October 6, 2026 |
| Wegovy (semaglutide): uses, side effects, cost and FDA status | Self-pay / cash | 349 USD | per month, pens 0.25 mg to 2.4 mg, NovoCare Pharmacy | October 6, 2026 |
| Wegovy (semaglutide): uses, side effects, cost and FDA status | Self-pay / cash | 399 USD | per month, Wegovy HD 7.2 mg pen, NovoCare Pharmacy | October 6, 2026 |
| Wegovy (semaglutide): uses, side effects, cost and FDA status | Self-pay / cash | 199 USD | per month, first 2 fills of 0.25 mg and 0.5 mg for new patients, through 2026-12-31 | October 6, 2026 |
| Wegovy (semaglutide): uses, side effects, cost and FDA status | With savings program | 25 USD | per month with commercial coverage (max savings $100 a month; government beneficiaries excluded) | October 6, 2026 |
Prices change often and depend on pharmacy, plan and location. Insurance can change what you pay. Every price shows the date we checked it.
Things people weigh up
- Approved use: Ozempic is for type 2 diabetes; Wegovy is for weight management (and heart risk and MASH). Using Ozempic for weight alone is off label.
- Dose: the highest Ozempic dose is 2 mg weekly; Wegovy goes to 2.4 mg, and Wegovy HD to 7.2 mg. In STEP 2, 2.4 mg led to more weight loss than 1.0 mg in people with diabetes.
- Coverage: plans usually cover Ozempic for diabetes; coverage of Wegovy for weight varies, and off-label Ozempic for weight is often not covered.
- Medicare: Part D covers Ozempic for diabetes; the temporary GLP-1 Bridge covers Wegovy for weight for people who meet its criteria.
- Forms: both have pens and tablets, but the tablets are different products with different approved uses and strengths.
- Side effects are the same in kind; label rates differ because of the doses and people studied.
These are the differences people commonly consider, not a recommendation. A clinician can help you decide what fits you.
In short: Ozempic and Wegovy contain the same active ingredient, semaglutide, and are made by the same company, Novo Nordisk. The difference is what the FDA approved each one for and at what doses. Ozempic is approved for adults with type 2 diabetes (blood-sugar control, plus heart and kidney protection in certain patients), up to 2 mg a week. Wegovy is approved for chronic weight management in adults and teens 12 and older, for heart-risk reduction in adults with heart disease and overweight or obesity, and for a fatty-liver disease called MASH, at doses up to 2.4 mg a week (7.2 mg with Wegovy HD). Ozempic is not FDA approved for weight loss (labels checked on October 6, 2026).
Because they are the same molecule, people often ask whether Ozempic “works the same” for weight. This page sets out what the labels and trials actually say, so you can discuss it with a licensed clinician. Whether either medicine is appropriate for you is a medical decision that needs an evaluation; InstaTuck does not sell or prescribe medicines.
Ozempic vs Wegovy at a glance
- Same moleculeboth are semaglutide, a GLP-1 receptor agonist, made by Novo NordiskFDA labels
- 2 mg vs 2.4 mghighest weekly dose on the Ozempic label vs Wegovy's standard maintenance dose (Wegovy HD: 7.2 mg)FDA labels
- -7.0% vs -9.6%average weight change at 68 weeks with semaglutide 1.0 mg vs 2.4 mg in adults with type 2 diabetes (STEP 2)Lancet 2021
Checked on October 6, 2026
The basics side by side
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA approved for weight management | No | Yes (adults; teens 12+ with obesity, injection) |
| Approved uses | Blood-sugar control in adults with type 2 diabetes; lower risk of major cardiovascular events in adults with type 2 diabetes and heart disease; lower risk of kidney decline, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease | Chronic weight management; lower risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight (no diabetes needed); MASH with moderate to advanced liver fibrosis (injection) |
| Weekly doses on the label | 0.25 mg to start, then 0.5, 1 and 2 mg | 0.25 mg to start, stepping up to 2.4 mg (1.7 mg if needed); Wegovy HD 7.2 mg for some adults |
| Forms | Multi-dose pens and single-dose syringes; Ozempic tablets (type 2 diabetes) | Single-dose pens; Wegovy pill (daily tablet, up to 25 mg) |
| Boxed warning | Thyroid C-cell tumors in rodents | Thyroid C-cell tumors in rodents |
| List price (manufacturer) | $1,027.51 per pen package | $1,349.02 per package |
Same medicine, different approvals: why it matters
An FDA approval covers a specific use, population and dose that were tested in trials. Ozempic’s trials were in people with type 2 diabetes and measured blood sugar, heart and kidney outcomes. Wegovy’s trials (the STEP program) were designed around weight, and SELECT tested heart outcomes in people with obesity but without diabetes. So even though the molecule is identical, each brand’s label only describes the uses that were proven for it.
When Ozempic is prescribed for weight loss in someone without diabetes, that is called off-label use. It is legal for a prescriber to do, but it is not an approved use, and insurance plans often do not cover it. Our page on Ozempic for weight loss covers that question in depth. The molecule itself, across all its brands, is explained on the semaglutide page, and the class on our GLP-1 guide.
Dose matters: what the trials showed
The cleanest comparison comes from STEP 2, a 68-week trial of 1,210 adults with type 2 diabetes and a BMI of 27 or more. People were randomly assigned to semaglutide 2.4 mg (the Wegovy dose), semaglutide 1.0 mg (an Ozempic dose) or placebo, all with lifestyle support, and neither participants nor investigators knew who was on which. Average weight change was -9.6% with 2.4 mg, -7.0% with 1.0 mg and -3.4% with placebo. The difference between the two doses, 2.7 percentage points, was statistically significant.
| Item | Value |
|---|---|
| Semaglutide 2.4 mg (Wegovy dose) | 9.6% |
| Semaglutide 1.0 mg (Ozempic dose) | 7% |
| Placebo | 3.4% |
Treatment-policy estimand. People with type 2 diabetes usually lose less weight on GLP-1 medicines than people without it.
Source: Davies M et al., Lancet 2021 (STEP 2, 1,210 adults) (checked on October 6, 2026)
In adults without diabetes, the key Wegovy trial was STEP 1: average weight change was -14.9% with 2.4 mg versus -2.4% with placebo at 68 weeks, and 86.4% versus 31.5% lost at least 5%. Ozempic has no comparable trial in people without diabetes because it was not developed for that use. For higher doses, Wegovy HD (7.2 mg) was studied in the STEP UP trials and is described on the Wegovy HD page.
| Item | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Lost 5% or more | 86.4% | 31.5% |
| Lost 10% or more | 69.1% | 12% |
| Lost 15% or more | 50.5% | 4.9% |
68-week trial with lifestyle intervention. Individual results vary.
Source: Wilding JPH et al., NEJM 2021 (STEP 1, 1,961 adults) (checked on October 6, 2026)
Heart and kidney outcomes
Both brands have outcome trials behind their extra indications, in different groups of people:
| Trial | Who was in it | Result | Brand it supports |
|---|---|---|---|
| SUSTAIN-6 | 3,297 adults with type 2 diabetes at high cardiovascular risk; semaglutide 0.5 or 1.0 mg for 104 weeks | Major cardiovascular events 6.6% vs 8.9% with placebo; more diabetic eye (retinopathy) complications with semaglutide | Ozempic |
| FLOW | 3,533 adults with type 2 diabetes and chronic kidney disease; semaglutide 1.0 mg; median 3.4 years | 24% lower risk of major kidney disease events (including kidney failure and kidney or cardiovascular death) | Ozempic |
| SELECT | 17,604 adults 45+ with heart disease and a BMI of 27+, without diabetes; semaglutide 2.4 mg | Major cardiovascular events 6.5% vs 8.0% with placebo | Wegovy |
| Item | Semaglutide | Placebo |
|---|---|---|
| SUSTAIN-6 (type 2 diabetes, 2 years) | 6.6% | 8.9% |
| SELECT (obesity or overweight, no diabetes, about 3.3 years) | 6.5% | 8% |
Different populations, doses and lengths; each trial compared semaglutide with placebo, not with the other brand.
Source: Marso SP et al., NEJM 2016 (SUSTAIN-6); Lincoff AM et al., NEJM 2023 (SELECT) (checked on October 6, 2026)
Side effects compared
The side effects are the same in kind because the drug is the same, but the label rates differ because the trials used different doses and different people. Ozempic’s numbers come from diabetes trials at 0.5 and 1 mg; Wegovy’s come from weight trials at 2.4 mg, where higher doses and a longer dose-increase period were used.
| Item | Ozempic 1 mg (diabetes trials) | Wegovy 2.4 mg (weight trials) |
|---|---|---|
| Nausea | 20.3% | 44% |
| Diarrhea | 8.8% | 30% |
| Vomiting | 9.2% | 24% |
| Constipation | 3.1% | 24% |
Placebo rates: Ozempic trials nausea 6.1, diarrhea 1.9, vomiting 2.3, constipation 1.5%; Wegovy trials 16, 16, 6, 11%. Different trials and doses; not a head-to-head comparison.
Source: Ozempic and Wegovy prescribing information (DailyMed), adverse reaction tables (checked on October 6, 2026)
Both labels share the same boxed warning (thyroid C-cell tumors in rodents; not used with a personal or family history of medullary thyroid carcinoma or MEN 2) and the same serious warnings: pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration, allergic reactions, diabetic eye complications in people with type 2 diabetes, a faster heart rate and aspiration during anesthesia or deep sedation. Ozempic’s label advises stopping at least 2 months before a planned pregnancy because semaglutide stays in the body for weeks. Full details: Ozempic side effects, Wegovy side effects and our GLP-1 side effects guide.
Cost and coverage (checked on October 6, 2026)
The two brands are priced differently even though they are the same molecule. Novo Nordisk lists Ozempic at $1,027.51 per pen package and Wegovy at $1,349.02 per package. Through its own NovoCare Pharmacy, self-pay prices are:
| Item | Ozempic | Wegovy |
|---|---|---|
| Starting strengths, first 2 fills (new patients) | $199 | $199 |
| Starting strengths after the offer | $349 | $349 |
| 1 mg (Ozempic) / 1 to 2.4 mg (Wegovy) | $349 | $349 |
| Top strength (Ozempic 2 mg / Wegovy HD 7.2 mg) | $499 | $399 |
Introductory $199 price: 0.25 and 0.5 mg, two monthly fills, through December 31, 2026. Tablets: Ozempic $149 to $299, Wegovy pill $149 to $299 a month by strength.
Source: NovoCare Pharmacy, Ozempic and Wegovy self-pay pricing (Novo Nordisk) (checked on October 6, 2026)
- Insurance. Plans usually cover Ozempic for type 2 diabetes. Coverage of Wegovy for weight management varies by plan and employer, often with prior authorization. Using Ozempic off label for weight is frequently not covered.
- Savings offer. With commercial insurance that covers the medicine, Novo Nordisk’s offer lets eligible people pay as little as $25 a month for either brand (maximum savings $100 a month). Government beneficiaries are excluded, although NovoCare says people with government insurance may use the self-pay prices if they pay outside their insurance.
- Medicare. Part D plans cover Ozempic for type 2 diabetes under their usual rules. Medicare cannot cover drugs used for weight loss by law, but the temporary Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Wegovy for weight management with a $50 copay for people who meet its criteria.
- What changes in 2027. Novo Nordisk has announced a $675 monthly list price for Wegovy and Ozempic from January 1, 2027. Separately, Medicare’s negotiated price for Ozempic, Rybelsus and Wegovy will be $274 for a 30-day supply in 2027, compared with a 2024 list price of $959.
Details by brand: Ozempic cost and Wegovy cost; coverage rules in does insurance cover GLP-1s?
Counterfeit and compounded semaglutide
The FDA has warned several times about counterfeit Ozempic 1 mg pens found in the U.S. supply chain (alerts in December 2023, April 2025 and December 2025), including a concern that needle sterility could not be confirmed. Its advice is to get medicines only from state-licensed pharmacies with a prescription and to check packaging before use. Compounded semaglutide is not Ozempic or Wegovy and is not FDA approved; see compounded GLP-1s.
Stopping, and what comes next
With either brand, weight tends to return after stopping: in STEP 4, people switched from semaglutide 2.4 mg to placebo regained 6.9% over 48 weeks, while those who continued lost a further 7.9%. People with diabetes should never stop a diabetes medicine without their prescriber, because blood sugar can rise. See life after a GLP-1 for what helps.
Related comparisons: Wegovy vs Zepbound, semaglutide vs tirzepatide and injections vs pills. Diabetes and weight are covered on insulin resistance, and all approved options are on the medications hub.
Compared with the items
FDA approved for another usePrescriptionInjectionOzempic (semaglutide): approved uses and how it differs from WegovySemaglutide: one ingredient, several brands · Injection · Weekly
FDA approved for weight managementPrescriptionInjectionWegovy (semaglutide): uses, side effects, cost and FDA statusSemaglutide: one ingredient, several brands · Injection · WeeklyRelated comparisons
Related guides
Ozempic for Weight Loss: what is approved, what is off label, what to askOzempic for weight loss explained: what the FDA label covers, what off-label use means, Ozempic vs…
GLP-1 Medications: how they work and which are approved for weightGLP-1 medications explained: what GLP-1 is, how the drugs work, which brands are FDA approved for…
GLP-1 Side Effects: common, serious and how they are managedGLP-1 side effects from the FDA labels: common digestive effects by brand, serious risks, the thyroid…
Stopping a GLP-1: regain, what trials show and keeping resultsWhat happens when you stop a GLP-1: STEP 1 extension, STEP 4, SURMOUNT-4 and BMJ meta-analysis…Questions to ask a professional
- Do I have type 2 diabetes, prediabetes or another condition that changes which semaglutide brand is appropriate?
- If you prescribe semaglutide for weight, why one brand rather than the other?
- What will my plan cover, and does prior authorization apply?
- What dose would we aim for, and how will we handle side effects while it increases?
- If I stop, how do we protect my blood sugar, heart health and weight?
Frequently asked questions
Is Ozempic the same as Wegovy?
They contain the same active ingredient, semaglutide, from the same maker. They differ in FDA-approved uses, doses, devices and price: Ozempic is approved for type 2 diabetes up to 2 mg a week; Wegovy is approved for weight management up to 2.4 mg (7.2 mg with Wegovy HD).
Is Ozempic FDA approved for weight loss?
No. Ozempic is approved for adults with type 2 diabetes. Prescribing it for weight loss alone is off-label use; Wegovy is the semaglutide brand approved for chronic weight management.
Do you lose the same amount of weight on Ozempic and Wegovy?
Dose matters. In STEP 2, in adults with type 2 diabetes, semaglutide 2.4 mg led to 9.6% average weight loss versus 7.0% with 1.0 mg. There is no large trial of Ozempic doses for weight in people without diabetes.
Can I switch from Ozempic to Wegovy?
Switching is a prescriber decision. The devices and doses are different, and the two must never be used together. Your prescriber will decide the starting dose and timing.
Why does Wegovy cost more than Ozempic?
They are priced separately. On 2026-10-06 the list prices were $1,027.51 per Ozempic pen package and $1,349.02 per Wegovy package. NovoCare self-pay prices were similar for most strengths ($349 a month), and both list prices drop to $675 a month from January 1, 2027.
Does Medicare cover Ozempic or Wegovy?
Part D covers Ozempic for type 2 diabetes. Medicare is barred by law from covering drugs used for weight loss, but the temporary GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Wegovy for weight management with a $50 copay for people who meet its criteria.
Are the side effects the same?
They are the same in kind (mostly nausea, diarrhea, vomiting and constipation) and share the same warnings. The label rates differ because the trials used different doses and people.
Is the Ozempic pill the same as the Wegovy pill?
No. Ozempic tablets (1.5, 4 and 9 mg) are approved for adults with type 2 diabetes, while the Wegovy pill (1.5 mg up to 25 mg) is approved for weight management and heart-risk reduction. Strengths and approved uses differ, so one is never swapped for the other without a prescriber. Compounded semaglutide is neither and is not FDA approved.
How do I avoid counterfeit Ozempic?
The FDA advises getting it only with a prescription from a state-licensed pharmacy, checking the packaging, and reporting concerns to the manufacturer or FDA MedWatch. It has issued counterfeit alerts in December 2023, April 2025 and December 2025.
References
- OZEMPIC (semaglutide) injection: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- Davies M, Faerch L, Jeppesen OK, et al.. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet, 2021. doi:10.1016/S0140-6736(21)00213-0 · PMID 33667417 · NCT03552757 (accessed October 6, 2026) Randomized trial
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. doi:10.1056/NEJMoa2032183 · PMID 33567185 · NCT03548935 (accessed October 7, 2026) Randomized trial
- Marso SP, Bain SC, Consoli A, et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine, 2016. doi:10.1056/NEJMoa1607141 · PMID 27633186 · NCT01720446 (accessed October 7, 2026) Randomized trial
- Perkovic V, Tuttle KR, Rossing P, et al.. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine, 2024. doi:10.1056/NEJMoa2403347 · PMID 38785209 · NCT03819153 (accessed October 7, 2026) Randomized trial
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, 2023. doi:10.1056/NEJMoa2307563 · PMID 37952131 · NCT03574597 (accessed October 7, 2026) Randomized trial
- Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA, 2021. doi:10.1001/jama.2021.3224 · PMID 33755728 · NCT03548987 (accessed October 7, 2026) Randomized trial
- Ozempic list price and insurance coverage explained. Novo Nordisk (NovoCare). (accessed October 6, 2026) Other
- Wegovy cost, coverage and savings resources. Novo Nordisk (NovoCare). (accessed October 6, 2026) Other
- Ozempic online pharmacy: self-pay prices and savings. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus. Novo Nordisk (press release), 2026. (accessed October 7, 2026) News (reported facts only)
- Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027. Centers for Medicare and Medicaid Services. (accessed October 6, 2026) Government page
- Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
- What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries. KFF, 2026. (accessed October 6, 2026) Other
- FDA warns consumers not to use counterfeit Ozempic found in U.S. drug supply chain. U.S. Food and Drug Administration, 2025. (accessed October 7, 2026) Government page
Facts checked on October 6, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.